Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results? - Suppr | 超能文献

Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results?

作者信息

Harvey Philip D

机构信息

Dr. Harvey is Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.

出版信息

Psychiatry (Edgmont). 2007 Sep;4(9):20-3.

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2880938/

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results?

Psychiatry (Edgmont). 2007 Sep;4(9):20-3.

2

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

Schizophr Res. 2005 Dec 1;80(1):19-32. doi: 10.1016/j.schres.2005.07.014. Epub 2005 Aug 30.

3

Antipsychotics and metabolics in the post-CATIE era.

Curr Top Behav Neurosci. 2010;4:23-42. doi: 10.1007/7854_2010_45.

4

Reach of benchmark psychiatric trial results to community-based providers: a case study of CATIE.

J Clin Psychiatry. 2008 Jul;69(7):1081-6. doi: 10.4088/jcp.v69n0706.

5

Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample.

Schizophr Res. 2011 May;128(1-3):61-5. doi: 10.1016/j.schres.2011.01.020. Epub 2011 Feb 24.

6

Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.

J Clin Psychiatry. 2007;68 Suppl 1:12-9.

7

Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.

J Clin Psychiatry. 2015 Nov;76(11):1535-45. doi: 10.4088/JCP.14m09320.

8

Understanding the results of CATIE in the context of the field.

CNS Spectr. 2006 Jul;11(7 Suppl 7):40-7. doi: 10.1017/s1092852900026675.

9

Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study.

Clin Schizophr Relat Psychoses. 2011 Oct;5(3):124-34. doi: 10.3371/CSRP.5.3.2.

10

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.

引用本文的文献

1

Antipsychotic medication-mediated cognitive change in schizophrenia and polygenic score for cognitive ability.

Schizophr Res Cogn. 2021 Nov 9;27:100223. doi: 10.1016/j.scog.2021.100223. eCollection 2022 Mar.

2

Education Mediates Racial Disparities in Cognitive Impairment Among Older Adults With Schizophrenia.

Clin Gerontol. 2023 Jan-Feb;46(1):66-79. doi: 10.1080/07317115.2021.1882021. Epub 2021 Feb 12.

3

Relapse risk assessment in early phase psychosis: the search for a reliable and valid tool.

Can J Psychiatry. 2014 Dec;59(12):655-8. doi: 10.1177/070674371405901207.

4

Dendritic spine pathology in schizophrenia.

Neuroscience. 2013 Oct 22;251:90-107. doi: 10.1016/j.neuroscience.2012.04.044. Epub 2012 Apr 27.

本文引用的文献

1

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Arch Gen Psychiatry. 2007 Jun;64(6):633-47. doi: 10.1001/archpsyc.64.6.633.

2

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Am J Psychiatry. 2006 Dec;163(12):2080-9. doi: 10.1176/ajp.2006.163.12.2080.

3

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Neuropsychopharmacology. 2006 Sep;31(9):2033-46. doi: 10.1038/sj.npp.1301072. Epub 2006 Apr 19.

4

Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.

J Neuropsychiatry Clin Neurosci. 2006 Winter;18(1):54-63. doi: 10.1176/jnp.18.1.54.

5

Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.

Am J Psychiatry. 2005 Oct;162(10):1888-95. doi: 10.1176/appi.ajp.162.10.1888.

6

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

N Engl J Med. 2005 Sep 22;353(12):1209-23. doi: 10.1056/NEJMoa051688. Epub 2005 Sep 19.

7

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.

Am J Psychiatry. 2005 May;162(5):947-53. doi: 10.1176/appi.ajp.162.5.947.

8

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

Int J Neuropsychopharmacol. 2005 Sep;8(3):457-72. doi: 10.1017/S146114570500516X. Epub 2005 Mar 23.

9

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.

Am J Psychiatry. 2004 Oct;161(10):1837-47. doi: 10.1176/ajp.161.10.1837.

10

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Am J Psychiatry. 2002 Jun;159(6):1018-28. doi: 10.1176/appi.ajp.159.6.1018.